Navigation Links
Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
Date:6/13/2008

VANCOUVER, June 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the market launch of Quill(TM) SRS MONODERM(TM). The product will be available immediately for distribution and sale in the U.S. and Europe.

Quill(TM) SRS MONODERM(TM), which is made from a rapidly resorbing polymer, is intended primarily for superficial wound closure applications and indicated for soft tissue approximation where use of an absorbable suture is appropriate.

"The launch of MONODERM(TM) is another example of the progress we have made in expanding the Quill(TM) SRS product line," said Dr. William Hunter, President and CEO of Angiotech. "MONODERM(TM) is intended primarily for skin closure and will complement Quill(TM) SRS which currently targets deeper layers of wound closure."

Forward Looking Statements

--------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our strategies or future actions, our targets, expectations for our financial condition and the results of, or outl
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
2. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
3. Angiotech appoints Hank McKinnell to its Board of Directors
4. Angiotech to participate in Bank of America Health Care Conference
5. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
6. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
7. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
8. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
9. Angiotech announces director resignation
10. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
11. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... 20, 2014 PureTech , a science ... healthcare problems, announced today the closing of a ... from Invesco Perpetual, a $120 Billion group of ... PureTech,s existing pipeline forward and to advance new ... scientific creativity to really go for the big ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The ... ABIM will take place at the Congress ... 2014 is now available at http://www.abim.ch ... and organizations from all over the globe ... the latest products and developments on the ...
(Date:10/19/2014)... 2014 The report "Chocolate, Cocoa Beans, ... Prices, Geography Trend and Forecast (2011 - 2016)," ... geography and studies the major market drivers, restraints, and ... and Asia. , The global chocolate market is expected ... in 2016 at an estimated CAGR of 2.7% from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... - New findings from the pivotal TEMSO Phase III study presented ... - U.S. FDA Accepts New Drug Application for   ... (EURONEXT: SAN and NYSE: SNY ) and its subsidiary Genzyme ... ultiple S clerosis O ral (TEMSO) Phase III trial showing ...
... scientists at the University of California at Berkeley ... viruses called M13 phages to serve as structural ... of properties. By controlling the physical environment ... into hierarchically organized thin-film structures, with complexity that ...
... Fla., Oct. 19, 2011 Physicians and scientists ... just released the results of their groundbreaking research ... Impairs Embryonic Reproductive Potential While Blastocyst Biopsy Does ... and Non-Biopsied Sibling Embryos.   The study, led ...
Cached Biology Technology:Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 2Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 3Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 4Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 5Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis 6Manufacturing goes viral 2Manufacturing goes viral 3Manufacturing goes viral 4Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 2Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 3
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
(Date:10/16/2014)... how the bowel lining develops and, in the process, ... , The researchers produced evidence that stem cells are ... a feature of the bowel lining, and believe these ... controversial finding as scientists are still divided on the ... Chin Wee Tan and Professor Tony Burgess from the ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... out at the University of Haifa has found that bees ... over nectar that does not comprise these substances at all. ... bee addicted, the researchers say.* Bees prefer nectar with ... not comprise these substances at all, a study from the ...
... School of Medicine,s (BUSM) Slone Epidemiology Center and Boston ... pre-pregnancy obesity and gestational weight gain are associated with ... participants from the Black Women,s Health Study. This study ... baby born at less than 37 weeks of gestation ...
... (February 10, 2010) New research from the Monell Center ... to both a family history of alcoholism and the child,s ... how liking for sweets differs among children based on underlying ... is rewarding to all kids and makes them feel good," ...
Cached Biology News:Are bees also addicted to caffeine and nicotine? 2Prepregnancy, obesity and gestational weight gain influence risk of preterm birth 2Intense sweets taste especially good to some kids 2
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... In Vitro Osteogenesis Assay Kit contains all ... a mature osteoblastic lineage, as determined by ... provides all the necessary reagents and a ... plate reader. This product is useful for ...
... As the world of discovery races ever ... you on the fast track. So our constant ... help accelerate your research. Thats why our Biomek ... platform thats as advanced as it is flexible. ...
... personal-sized Thermal Cycler is the ideal instrument for ... range of PCR applications. Get Applied ... Save lab space without sacrificing results. ... Industry-Standard PCR Technology You Can Afford ...
Biology Products: